Who Paid My Doc
A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older.
ClinicalTrials.gov NCT06237296
Research payments
$4,110,418
Through program year 2025, $4,110,418 in research payments was reported against A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older., across 221 payments, paid by Sanofi Pasteur Inc..
- Paid by
- Sanofi Pasteur Inc.
- ClinicalTrials.gov
- NCT06237296
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $431,961 | 61 |
| 2024 | Research | $3,678,457 | 160 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Kelly Lambright Denver, CO Named on 36 payments
- Mark Leibowitz Gardena, CA Named on 29 payments
- Mark Turner Meridian, ID Named on 24 payments
- Margaret Rhee Akron, OH Named on 20 payments
- Frank Eder Johnson City, NY Named on 19 payments
- Nicholas Bechtold Sioux City, IA Named on 16 payments
- Lydia Bazzano Metairie, LA Named on 15 payments
- Julio Vijil Miami, FL Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.